While the global medical community pinned hopes on AstraZeneca, COVID-19 vaccine candidate developed by the University of Oxford and British-Swedish firm, clinical trails came to an abrupt halt on Tuesday after a participant developed an unexplained illness.
It is likely to be taken up by a safety expert group which will review information collected from the first set of participants in the human clinical trials in India. After which the clinical trials in India by Pune based Serum Institute of India (SII) in affiliation with Oxford fell in oblivion.
Amid the media speculations over the trails in India, the world’s largest vaccine maker, has signed an agreement to manufacture the potential vaccine developed by the Jenner Institute of Oxford University on Tuesday issued an official statement clearing the air.
SII clarified that the Indian trials of the vaccine candidate are continuing without any problems. ““We can’t comment on reports of AstraZeneca pausing the trials in the UK, other than that they have been paused for review and shall restart soon. The Indian trials are continuing and we have faced no issues at all,” read the statement.
It can be noted that over 100 volunteers in India have completed the crucial week after receiving shots in phase two human trials without showing any adverse reaction. Of which, 34 were from Bharti Vidyapeeth Medical College and hospital in Pune, who have been administered vaccine shots after trials for phase two began in India on August 26.
Rounding off, the spotlight is now on trails in India while countries, where the vaccine candidate is being tested, include Brazil and South Africa.